Genmab A (GMAB) Other Non-Current Liabilities (2018 - 2026)

Genmab A (GMAB) has reported Other Non-Current Liabilities for 9 consecutive years, with $5.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Liabilities rose 25.0% year-over-year to $5.0 million; the trailing twelve-month figure through Jun 2026 stood at $5.0 million (up 25.0% YoY), and the FY2025 full-year result was $5.0 million, changed 0.0% from the prior year.
• Other Non-Current Liabilities was little changed at $5.0 million in Q2 2026 per GMAB's latest filing, from $5.0 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $134.3 million in Q1 2022 and bottomed at $203887.9 in Q2 2022.
• Historically, Other Non-Current Liabilities has averaged $10.1 million across 5 years, with a median of $3.1 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities surged 112447.25% in 2022, then sank 97.93% in 2023.
• Over 5 years, Other Non-Current Liabilities stood at $1.0 million in 2022, then soared by 220.32% to $3.3 million in 2023, then surged by 52.07% to $5.0 million in 2024, then changed by 0.0% to $5.0 million in 2025, then changed by 0.0% to $5.0 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $5.0 million, $5.0 million, and $5.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.